Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria.

Rengarajan J, Sassetti CM, Naroditskaya V, Sloutsky A, Bloom BR, Rubin EJ.

Mol Microbiol. 2004 Jul;53(1):275-82.

2.

Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance.

Minato Y, Thiede JM, Kordus SL, McKlveen EJ, Turman BJ, Baughn AD.

Antimicrob Agents Chemother. 2015 Sep;59(9):5097-106. doi: 10.1128/AAC.00647-15. Epub 2015 Jun 1. Review.

3.

[Resistance to antituberculous drugs].

Veziris N, Cambau E, Sougakoff W, Robert J, Jarlier V.

Arch Pediatr. 2005 Aug;12 Suppl 2:S102-9. Review. French.

PMID:
16129320
4.

Tuberculosis: drug resistance, fitness, and strategies for global control.

Böttger EC, Springer B.

Eur J Pediatr. 2008 Feb;167(2):141-8. Epub 2007 Nov 7. Review.

PMID:
17987316
5.

The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria.

Singh P, Mishra AK, Malonia SK, Chauhan DS, Sharma VD, Venkatesan K, Katoch VM.

J Commun Dis. 2006 Mar;38(3):288-98. Review.

PMID:
17373362
6.

Molecular basis of antifolate resistance.

Assaraf YG.

Cancer Metastasis Rev. 2007 Mar;26(1):153-81. Review.

PMID:
17333344
7.

Strategies for potentiation of ethionamide and folate antagonists against Mycobacterium tuberculosis.

Wolff KA, Nguyen L.

Expert Rev Anti Infect Ther. 2012 Sep;10(9):971-81. doi: 10.1586/eri.12.87. Review.

8.

Pterin transport and metabolism in Leishmania and related trypanosomatid parasites.

Ouellette M, Drummelsmith J, El-Fadili A, Kündig C, Richard D, Roy G.

Int J Parasitol. 2002 Apr;32(4):385-98. Review.

PMID:
11849635
9.

THE MECHANISM OF ACTION OF THE FOLATE ANTAGONISTS IN MAN.

BERTINO JR.

Cancer Res. 1963 Sep;23:1286-306. Review. No abstract available.

Supplemental Content

Support Center